Specificity of rituximab and complement-mediated lysis.

Peripheral blood T lymphocytes were mixed with DHL-4 B cells and incubated for 3 hours at 37°C with 25% human serum alone (A,C; control) or in the presence of 10 μg/mL rituximab (B,D; CDC). Cells were then washed, stained with propidium iodide, and analyzed on the FACS. (A,B) Results of scatter analysis. (C,D) Results of dot plots of the red fluorescence. The percentages of cells in both the control and CDC panels are shown at the bottom. The results are representative of 2 separate experiments.